Botanical and Plant-derived Drugs: Global Markets
Summary:
The global market for botanical and plant-derived drugs is expected to grow from $38.7 billion in 2025 and is projected to reach $58.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2025 to 2030.
The use of conventional treatments based on regional herbs, combined with technological advancements, has gained popularity in recent decades for treating wounds and illnesses. New bioactive compounds derived from plants have been developed as a result, although post-marketing studies and clinical trials have not been successful enough to meet FDA regulations.
Throughout history, plants have been utilized as a source of medicine, and they still form the basis of many modern medications. But even though botanical medicine served as the foundation for the modern pharmaceutical industry, synthetic techniques in drug development are now commonplace.
The pharmaceutical and biotech industries have accepted the new reality brought about by science-driven translational research and botanical development, resulting in significant shifts in approaches, technology, and disciplines.
Report Scope
The report provides an overview of the global market for botanical and plant-derived drugs and analyzes market trends. It includes global revenue ($ million) for 2024 as the base year data and estimated data for the forecast period, which is 2025 through 2030. The market is segmented based on product, application and region. By type, the market is segmented into plant-derived drugs and botanicals.
This report primarily focuses on drugs, rather than supplements or dietary substitutes. By application, the market is segmented into cancer, cardiovascular diseases, central nervous system disorders, infectious diseases and other. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with additional focus on major countries in these regions. North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. The Asia-Pacific region includes China, Japan, India, South Korea, and the Rest of Asia-Pacific. Rest of the world includes South America and Middle East and Africa.
This report focuses on the significant driving trends and challenges that affect the market. It analyzes environmental, social, and corporate governance (ESG) developments. The report includes an analysis of the competitive landscape, with a focus on the key firms in the global market. It also has a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments.
Report Includes
The global market for botanical and plant-derived drugs is expected to grow from $38.7 billion in 2025 and is projected to reach $58.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2025 to 2030.
The use of conventional treatments based on regional herbs, combined with technological advancements, has gained popularity in recent decades for treating wounds and illnesses. New bioactive compounds derived from plants have been developed as a result, although post-marketing studies and clinical trials have not been successful enough to meet FDA regulations.
Throughout history, plants have been utilized as a source of medicine, and they still form the basis of many modern medications. But even though botanical medicine served as the foundation for the modern pharmaceutical industry, synthetic techniques in drug development are now commonplace.
The pharmaceutical and biotech industries have accepted the new reality brought about by science-driven translational research and botanical development, resulting in significant shifts in approaches, technology, and disciplines.
Report Scope
The report provides an overview of the global market for botanical and plant-derived drugs and analyzes market trends. It includes global revenue ($ million) for 2024 as the base year data and estimated data for the forecast period, which is 2025 through 2030. The market is segmented based on product, application and region. By type, the market is segmented into plant-derived drugs and botanicals.
This report primarily focuses on drugs, rather than supplements or dietary substitutes. By application, the market is segmented into cancer, cardiovascular diseases, central nervous system disorders, infectious diseases and other. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with additional focus on major countries in these regions. North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. The Asia-Pacific region includes China, Japan, India, South Korea, and the Rest of Asia-Pacific. Rest of the world includes South America and Middle East and Africa.
This report focuses on the significant driving trends and challenges that affect the market. It analyzes environmental, social, and corporate governance (ESG) developments. The report includes an analysis of the competitive landscape, with a focus on the key firms in the global market. It also has a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments.
Report Includes
- 47 data tables and 47 additional tables
- An overview of the global market for botanical and plant-derived drugs
- In-depth analysis of global market trends, featuring historical revenue data for 2022–2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
- Evaluation of the current market size and revenue growth prospects specific to the botanical and plant-derived drugs, accompanied by a market share analysis by type, application and region
- Analysis of current and future demand in the botanical and plant-derived drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
- Detailed information on some of the botanical or plant products that have received FDA approval for prescription medications, such as Veregen and Fulyzaq, and a discussion of their therapeutic advantages over synthetic substitutes
- Analysis of drivers, challenges and opportunities affecting market growth
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Market share analysis of the key market participants of the industry, along with their research priorities, product portfolios, global rankings and competitive landscape
- Profiles of major companies within the industry, including Bayer, Novartis, Jaguar Health Inc., Jazz Pharmaceuticals, and Bristol Myers Squibb Co.
CHAPTER 1 EXECUTIVE SUMMARY
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Emerging Technologies
Conclusion
CHAPTER 2 MARKET OVERVIEW
Overview
History of Plant-Derived Medicines
Ancient Egyptian Healing Practices (Circa 1500 BCE)
Chinese Herbal Medicine (Ancient times)
Plant-Derived Products in the Traditional Pharmacopeias
Quinine: A Malaria Breakthrough from Cinchona (17th Century)
Aspirin: A Gift from the Willow Tree (19th Century)
Botanical Drugs Value Chain
Cultivation and Collection
Primary Processing
Regulatory, Manufacturing and Consumers
Macroeconomic Factors Analysis
Demographic Factors
Geopolitical Factors
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Potential of New Entrants: Moderate to High
Bargaining Power of Suppliers: Moderate to High
Bargaining Power of Buyers: Moderate
Threat of Substitute Products or Services: Moderate
Level of Competitiveness: High
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Shift in Consumer Preference for Natural-Origin Therapeutics
Favorable Safety and Tolerability Profile
Advances in Extraction, Purification, and Analytical Technologies
Aging Population and the Growing Prevalence of Chronic Diseases
Supportive Regulatory Frameworks
Market Restraints
Complex Composition and Lack of Standardization
Lack of Funding for Botanical Drugs R&D
Market Opportunities
Application of Plant Metabolites for Drug Discovery
Growing Biotechnological Integration for Personalized Medicine Development
CHAPTER 4 REGULATORY LANDSCAPE
Overview
U.S.
Europe
Other Countries
CHAPTER 5 EMERGING TECHNOLOGIESAND DEVELOPMENTS
Key Takeaways
Single-Omics Approaches
Multi-Omics Approaches
Fermentation Technology
Pipeline Analysis
Key Takeaways
CHAPTER 6 MARKET SEGMENTATION ANALYSIS
Segmentation Breakdown
Market Analysis by Product Type
Key Takeaways
Botanical Drugs
Plant-Derived Drugs
Market Analysis by Application
Key Takeaways
Cancer
Cardiovascular Diseases
Central Nervous System Disorders
Infectious Diseases
Others
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 7 COMPETITIVE INTELLIGENCE
Key Takeaways
Competitive Analysis
Large Pharmaceutical Companies
Botanical Drug Companies
Strategic Initiatives
CHAPTER 8 SUSTAINABILITY IN THE BOTANICAL AND PLANT-DERIVED DRUGS MARKET: AN ESG PERSPECTIVE
Introduction to ESG
Sustainability Trends and Initiatives of the Botanical and Plant-Derived Drugs Industry
Concluding Remarks
CHAPTER 9 APPENDIX
Research Methodology
Sources
Acronyms
Company Profiles
ANI PHARMACEUTICALS INC.
BAYER AG
BRISTOL-MYERS SQUIBB CO.
CHIESI FARMACEUTICI S.P.A.
FRESENIUS KABI AG
GSK PLC
JAGUAR HEALTH
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON
MALLINCKRODT
MEDIWOUND
NOVARTIS AG
PFIZER INC.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Start-ups/Market Disruptors
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Emerging Technologies
Conclusion
CHAPTER 2 MARKET OVERVIEW
Overview
History of Plant-Derived Medicines
Ancient Egyptian Healing Practices (Circa 1500 BCE)
Chinese Herbal Medicine (Ancient times)
Plant-Derived Products in the Traditional Pharmacopeias
Quinine: A Malaria Breakthrough from Cinchona (17th Century)
Aspirin: A Gift from the Willow Tree (19th Century)
Botanical Drugs Value Chain
Cultivation and Collection
Primary Processing
Regulatory, Manufacturing and Consumers
Macroeconomic Factors Analysis
Demographic Factors
Geopolitical Factors
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Potential of New Entrants: Moderate to High
Bargaining Power of Suppliers: Moderate to High
Bargaining Power of Buyers: Moderate
Threat of Substitute Products or Services: Moderate
Level of Competitiveness: High
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Shift in Consumer Preference for Natural-Origin Therapeutics
Favorable Safety and Tolerability Profile
Advances in Extraction, Purification, and Analytical Technologies
Aging Population and the Growing Prevalence of Chronic Diseases
Supportive Regulatory Frameworks
Market Restraints
Complex Composition and Lack of Standardization
Lack of Funding for Botanical Drugs R&D
Market Opportunities
Application of Plant Metabolites for Drug Discovery
Growing Biotechnological Integration for Personalized Medicine Development
CHAPTER 4 REGULATORY LANDSCAPE
Overview
U.S.
Europe
Other Countries
CHAPTER 5 EMERGING TECHNOLOGIESAND DEVELOPMENTS
Key Takeaways
Single-Omics Approaches
Multi-Omics Approaches
Fermentation Technology
Pipeline Analysis
Key Takeaways
CHAPTER 6 MARKET SEGMENTATION ANALYSIS
Segmentation Breakdown
Market Analysis by Product Type
Key Takeaways
Botanical Drugs
Plant-Derived Drugs
Market Analysis by Application
Key Takeaways
Cancer
Cardiovascular Diseases
Central Nervous System Disorders
Infectious Diseases
Others
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 7 COMPETITIVE INTELLIGENCE
Key Takeaways
Competitive Analysis
Large Pharmaceutical Companies
Botanical Drug Companies
Strategic Initiatives
CHAPTER 8 SUSTAINABILITY IN THE BOTANICAL AND PLANT-DERIVED DRUGS MARKET: AN ESG PERSPECTIVE
Introduction to ESG
Sustainability Trends and Initiatives of the Botanical and Plant-Derived Drugs Industry
Concluding Remarks
CHAPTER 9 APPENDIX
Research Methodology
Sources
Acronyms
Company Profiles
ANI PHARMACEUTICALS INC.
BAYER AG
BRISTOL-MYERS SQUIBB CO.
CHIESI FARMACEUTICI S.P.A.
FRESENIUS KABI AG
GSK PLC
JAGUAR HEALTH
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON
MALLINCKRODT
MEDIWOUND
NOVARTIS AG
PFIZER INC.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Start-ups/Market Disruptors
LIST OF TABLES
Summary Table : Global Market for Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 1 : Important Natural Products Derived from Plants
Table 2 : Global Incidence and Mortality Cancer Rates, by WHO Region, 2022
Table 3 : Natural Products Classified as Medicines in Different Jurisdictions
Table 4 : EU Regulation of Herbal Medicinal Products
Table 5 : Regulation of Herbal Medicinal Products
Table 6 : Botanical Drugs in Development
Table 7 : Global Market for Botanical and Plant-Derived Drugs, by Product Type, Through 2030
Table 8 : Global Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 9 : Global Market for Cancer Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 10 : Global Market for Cardiovascular Disease Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 11 : Global Market for Central Nervous System Disorder Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 12 : Global Market for Infectious Disease Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 13 : Global Market for Other Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 14 : Global Market for Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 15 : North American Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 16 : North American Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
Table 17 : U.S. Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 18 : Canadian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 19 : Mexican Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 20 : European Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 21 : European Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
Table 22 : Percentage of Indications for Using Herbal Medicines in Germany
Table 23 : German Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 24 : U.K. Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 25 : French Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 26 : Spanish Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 27 : Italian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 28 : Rest of Europe Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 29 : Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 30 : Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
Table 31 : Chinese Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 32 : Japanese Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 33 : Indian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 34 : South Korean Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 35 : Rest of Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 36 : Rest of the World Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 37 : Rest of the World Market for Botanical and Plant-Derived Drugs, by Sub-Region, Through 2030
Table 38 : Strategic Initiatives in the Botanical and Plant-Derived Drugs Market, 2021-2025
Table 39 : Information Sources in this Report
Table 40 : Abbreviations Used in the Botanical and Plant-Derived Drugs Market
Table 41 : ANI Pharmaceuticals Inc.: Company Snapshot
Table 42 : ANI Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 43 : ANI Pharmaceuticals Inc.: Product Portfolio
Table 44 : Bayer AG: Company Snapshot
Table 45 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 46 : Bayer AG: Product Portfolio
Table 47 : Bayer AG: News/Recent Developments, 2024-2025
Table 48 : Bristol-Myers Squibb Co.: Company Snapshot
Table 49 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 50 : Bristol-Myers Squibb Co.: Product Portfolio
Table 51 : CHIESI Farmaceutici S.p.A.: Company Snapshot
Table 52 : CHIESI Farmaceutici S.p.A.: Financial Performance, FY 2023 and 2024
Table 53 : CHIESI Farmaceutici S.p.A.: Product Portfolio
Table 54 : CHIESI Farmaceutici S.p.A.: News/Key Developments, 2023
Table 55 : Fresenius Kabi AG: Company Snapshot
Table 56 : Fresenius Kabi AG: Financial Performance, FY 2023 and 2024
Table 57 : Fresenius Kabi AG: Product Portfolio
Table 58 : GSK plc: Company Snapshot
Table 59 : GSK plc: Financial Performance, FY 2023 and 2024
Table 60 : GSK plc: Product Portfolio
Table 61 : GSK plc: News/Key Developments, 2022
Table 62 : Jaguar Health: Company Snapshot
Table 63 : Jaguar Health: Financial Performance, FY 2023 and 2024
Table 64 : Jaguar Health: Product Portfolio
Table 65 : Jaguar Health: News/Key Developments, 2023-2025
Table 66 : Jazz Pharmaceuticals Inc.: Company Snapshot
Table 67 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 68 : Jazz Pharmaceuticals Inc.: Product Portfolio
Table 69 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2021
Table 70 : Johnson & Johnson: Company Snapshot
Table 71 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 72 : Johnson & Johnson: Product Portfolio
Table 73 : Mallinckrodt: Company Snapshot
Table 74 : Mallinckrodt: Financial Performance, FY 2023 and 2024
Table 75 : Mallinckrodt: Product Portfolio
Table 76 : MediWound: Company Snapshot
Table 77 : MediWound: Financial Performance, FY 2023 and 2024
Table 78 : MediWound: Product Portfolio
Table 79 : MediWound: News/Key Developments, 2022-2024
Table 80 : Novartis AG: Company Snapshot
Table 81 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 82 : Novartis AG: Product Portfolio
Table 83 : Novartis AG: News/Key Developments, 2024
Table 84 : Pfizer Inc.: Company Snapshot
Table 85 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 86 : Pfizer Inc.: Product Portfolio
Table 87 : Sanofi: Company Snapshot
Table 88 : Sanofi: Financial Performance, FY 2023 and 2024
Table 89 : Sanofi: Product Portfolio
Table 90 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 91 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 92 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 93 : List of a Few Emerging Startups in the Botanical and Plant-Derived Drugs Market
Summary Table : Global Market for Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 1 : Important Natural Products Derived from Plants
Table 2 : Global Incidence and Mortality Cancer Rates, by WHO Region, 2022
Table 3 : Natural Products Classified as Medicines in Different Jurisdictions
Table 4 : EU Regulation of Herbal Medicinal Products
Table 5 : Regulation of Herbal Medicinal Products
Table 6 : Botanical Drugs in Development
Table 7 : Global Market for Botanical and Plant-Derived Drugs, by Product Type, Through 2030
Table 8 : Global Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 9 : Global Market for Cancer Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 10 : Global Market for Cardiovascular Disease Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 11 : Global Market for Central Nervous System Disorder Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 12 : Global Market for Infectious Disease Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 13 : Global Market for Other Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 14 : Global Market for Botanical and Plant-Derived Drugs, by Region, Through 2030
Table 15 : North American Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 16 : North American Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
Table 17 : U.S. Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 18 : Canadian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 19 : Mexican Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 20 : European Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 21 : European Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
Table 22 : Percentage of Indications for Using Herbal Medicines in Germany
Table 23 : German Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 24 : U.K. Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 25 : French Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 26 : Spanish Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 27 : Italian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 28 : Rest of Europe Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 29 : Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 30 : Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
Table 31 : Chinese Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 32 : Japanese Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 33 : Indian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 34 : South Korean Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 35 : Rest of Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 36 : Rest of the World Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
Table 37 : Rest of the World Market for Botanical and Plant-Derived Drugs, by Sub-Region, Through 2030
Table 38 : Strategic Initiatives in the Botanical and Plant-Derived Drugs Market, 2021-2025
Table 39 : Information Sources in this Report
Table 40 : Abbreviations Used in the Botanical and Plant-Derived Drugs Market
Table 41 : ANI Pharmaceuticals Inc.: Company Snapshot
Table 42 : ANI Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 43 : ANI Pharmaceuticals Inc.: Product Portfolio
Table 44 : Bayer AG: Company Snapshot
Table 45 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 46 : Bayer AG: Product Portfolio
Table 47 : Bayer AG: News/Recent Developments, 2024-2025
Table 48 : Bristol-Myers Squibb Co.: Company Snapshot
Table 49 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 50 : Bristol-Myers Squibb Co.: Product Portfolio
Table 51 : CHIESI Farmaceutici S.p.A.: Company Snapshot
Table 52 : CHIESI Farmaceutici S.p.A.: Financial Performance, FY 2023 and 2024
Table 53 : CHIESI Farmaceutici S.p.A.: Product Portfolio
Table 54 : CHIESI Farmaceutici S.p.A.: News/Key Developments, 2023
Table 55 : Fresenius Kabi AG: Company Snapshot
Table 56 : Fresenius Kabi AG: Financial Performance, FY 2023 and 2024
Table 57 : Fresenius Kabi AG: Product Portfolio
Table 58 : GSK plc: Company Snapshot
Table 59 : GSK plc: Financial Performance, FY 2023 and 2024
Table 60 : GSK plc: Product Portfolio
Table 61 : GSK plc: News/Key Developments, 2022
Table 62 : Jaguar Health: Company Snapshot
Table 63 : Jaguar Health: Financial Performance, FY 2023 and 2024
Table 64 : Jaguar Health: Product Portfolio
Table 65 : Jaguar Health: News/Key Developments, 2023-2025
Table 66 : Jazz Pharmaceuticals Inc.: Company Snapshot
Table 67 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 68 : Jazz Pharmaceuticals Inc.: Product Portfolio
Table 69 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2021
Table 70 : Johnson & Johnson: Company Snapshot
Table 71 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 72 : Johnson & Johnson: Product Portfolio
Table 73 : Mallinckrodt: Company Snapshot
Table 74 : Mallinckrodt: Financial Performance, FY 2023 and 2024
Table 75 : Mallinckrodt: Product Portfolio
Table 76 : MediWound: Company Snapshot
Table 77 : MediWound: Financial Performance, FY 2023 and 2024
Table 78 : MediWound: Product Portfolio
Table 79 : MediWound: News/Key Developments, 2022-2024
Table 80 : Novartis AG: Company Snapshot
Table 81 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 82 : Novartis AG: Product Portfolio
Table 83 : Novartis AG: News/Key Developments, 2024
Table 84 : Pfizer Inc.: Company Snapshot
Table 85 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 86 : Pfizer Inc.: Product Portfolio
Table 87 : Sanofi: Company Snapshot
Table 88 : Sanofi: Financial Performance, FY 2023 and 2024
Table 89 : Sanofi: Product Portfolio
Table 90 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 91 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 92 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 93 : List of a Few Emerging Startups in the Botanical and Plant-Derived Drugs Market
LIST OF FIGURES
Summary Figure : Global Market Shares of Botanical and Plant-Derived Drugs, by Region, 2024
Figure 1 : Botanical Drugs Value Chain
Figure 2 : Porter’s Five Forces Analysis of the Botanical and Plant-Derived Drugs Market
Figure 3 : Market Dynamics of Botanical and Plant-Derived Drugs
Figure 4 : Global Market Shares of Botanical and Plant-Derived Drugs, by Product Type, 2024
Figure 5 : Global Market Shares of Botanical and Plant-Derived Drugs, by Application Type, 2024
Figure 6 : Global Market Shares of Botanical and Plant-Derived Drugs, by Region, 2024
Figure 7 : North American Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
Figure 8 : European Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
Figure 9 : Asia-Pacific Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
Figure 10 : Rest of the World Market Shares of Botanical and Plant-Derived Drugs, by Sub-Region, 2024
Figure 11 : ANI Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 12 : ANI Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 13 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
Figure 14 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
Figure 15 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 16 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 17 : CHIESI Farmaceutici S.p.A.: Revenue Shares, by Business Unit, FY 2024
Figure 18 : CHIESI Farmaceutici S.p.A.: Revenue Shares, by Country/Region, FY 2024
Figure 19 : Fresenius Kabi AG: Revenue Shares, by Business Unit, FY 2024
Figure 20 : GSK plc: Revenue Shares, by Business Unit, FY 2024
Figure 21 : GSK plc: Revenue Shares, by Country/Region, FY 2024
Figure 22 : Jaguar Health: Revenue Shares, by Business Unit, FY 2024
Figure 23 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 24 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 25 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
Figure 26 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
Figure 27 : Mallinckrodt: Revenue Shares, by Business Unit, FY 2024
Figure 28 : Mallinckrodt: Revenue Shares, by Country/Region, FY 2024
Figure 29 : MediWound: Revenue Shares, by Country/Region, FY 2024
Figure 30 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 31 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 32 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 33 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 34 : Sanofi: Revenue Shares, by Country/Region, FY 2024
Figure 35 : Teva Pharmaceutical Industries Ltd.: Market Shares, by Country/Region, FY 2024
Summary Figure : Global Market Shares of Botanical and Plant-Derived Drugs, by Region, 2024
Figure 1 : Botanical Drugs Value Chain
Figure 2 : Porter’s Five Forces Analysis of the Botanical and Plant-Derived Drugs Market
Figure 3 : Market Dynamics of Botanical and Plant-Derived Drugs
Figure 4 : Global Market Shares of Botanical and Plant-Derived Drugs, by Product Type, 2024
Figure 5 : Global Market Shares of Botanical and Plant-Derived Drugs, by Application Type, 2024
Figure 6 : Global Market Shares of Botanical and Plant-Derived Drugs, by Region, 2024
Figure 7 : North American Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
Figure 8 : European Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
Figure 9 : Asia-Pacific Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
Figure 10 : Rest of the World Market Shares of Botanical and Plant-Derived Drugs, by Sub-Region, 2024
Figure 11 : ANI Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 12 : ANI Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 13 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
Figure 14 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
Figure 15 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 16 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 17 : CHIESI Farmaceutici S.p.A.: Revenue Shares, by Business Unit, FY 2024
Figure 18 : CHIESI Farmaceutici S.p.A.: Revenue Shares, by Country/Region, FY 2024
Figure 19 : Fresenius Kabi AG: Revenue Shares, by Business Unit, FY 2024
Figure 20 : GSK plc: Revenue Shares, by Business Unit, FY 2024
Figure 21 : GSK plc: Revenue Shares, by Country/Region, FY 2024
Figure 22 : Jaguar Health: Revenue Shares, by Business Unit, FY 2024
Figure 23 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 24 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 25 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
Figure 26 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
Figure 27 : Mallinckrodt: Revenue Shares, by Business Unit, FY 2024
Figure 28 : Mallinckrodt: Revenue Shares, by Country/Region, FY 2024
Figure 29 : MediWound: Revenue Shares, by Country/Region, FY 2024
Figure 30 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 31 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 32 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 33 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 34 : Sanofi: Revenue Shares, by Country/Region, FY 2024
Figure 35 : Teva Pharmaceutical Industries Ltd.: Market Shares, by Country/Region, FY 2024
